Oritavancin diphosphate Clinical Study Protocol MDCO-ORI-16 -02 
The Medicines Company 
Confidential 1 Ini
tial U.S. Approval: 2014 
ORBACTIV™ (oritavancin) 
A DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE THE 
SAFETY OF EITHER A SINGLE 1200-MG INTRAVENOUS (IV) DOSE OF 
ORBACTIV™ (ORITAVANCIN) AND PLACEBO OR TWO IV DOSES OF 
ORBACTIV™ IN SUBJECTS BEING TREATED FOR ACUTE 
BACTERIAL SKIN AND SKIN STRUCTURE INFECTION 
Protocol No.:  MDCO -ORI -16-02 
U.S. IND No.: 51,292  
EudraCT No.:  Not Applicable  
PROTOCOL VERSION:  1.0 
Development Phase:  IV 
Sponsor:  The Medicines Company  
8 Sylvan Way  
Parsippany, NJ 07054  
Principal Investigator:   
Sponsor Representatives:  
Medical Director:  Name:   
Project Leader:  Name:   
Global  Safety Officer:  Name:   
Issue Date:  Date:  19 OCTOBER  2016  
CONFIDENTIAL 
Property of The Medicines Company 
May not be used, divulged, published or otherwise disclosed without the consent of 
The Medicines Company 
This study will be conducted in compliance with Good Clinical Practice (GCP) and protection of the subject 
as required by the regulations and directives in operation at this time. NCT #: [STUDY_ID_REMOVED]

Oritavancin diphosphate  Clinical Study Protocol MDCO-ORI-16-02 
The
 Medicines Company  
 
Confidential  2 
 P
ROCEDURES IN CASE OF EMERGENCY 
 
Emergency Contact Information  
Role in Study  Name:  Telephone Number:  
24-Hour Emergency Contact    (US)  
 
Medical Director    
Global Safety Officer    
Study Manager    
 
 

Oritavancin diphosphate  Clinical Study Protocol MDCO-ORI-16-02 
The
 Medicines Company  
 
Confidential  3 
 P
ROTOCOL SYNOPSIS 
 
Name of Sponsor/Company :   The Medicines Company  
Name of Finished Drug/Device :  ORBACTIV™ (oritavancin)  
Name of Active Ingredient :  Oritavancin diphosphate  
Title of Study :  A Double -Blind, Randomize d Study to Evaluate the Safety of either a Single 1200 -mg 
Intravenous ( IV) Dose of Orbactiv™ (oritavancin) and Placebo or two IV Doses of Orbactiv™ in Subjects Being 
Treated f or Acute Bacte rial Skin and Sk in Structure Infection (ABSSSI)  
Phase of Development :  IV 
Study Centers : Multicenter study  in up to 5 centers in the United States  
Central Facilities :  This list is maintained by the Sponsor  
Number of Subjects : 20 planned; 20  evaluable  
Principal Investigator :    
Study Period :  The estimated study period for the study will be approximately 3 weeks  from first subject 
enrolled to last subject completed.  
Objectives :  Assess the safety and tolerability of two 1200 -mg intravenous (IV) infusions of oritavancin when 
administered one week apart in subjects with acute bacterial skin and skin structure infection (ABSSSI) . 
Methodology : This study will be a randomized, double -blind study.  Subjects with will be randomized (3 :1) to 
receive either two doses of oritavancin or one dose of oritavancin and a single dose of placebo one week apart in 
order  to obtain safety information. This safety information will include information regarding the potential for 
antibody production fo llowing one or two doses of 1200  mg oritavancin.   
Diagnosis and Main Criteria for Selection :  
Key inclusion criteria:  
 Males or females ≥ 18 years old  
 Diagnosi s of ABSSSI (wound infections, c ellulitis/erysipelas, or cutaneous abscess) suspected or 
confirmed to be caused by a Gram -positive pathogen requiring IV therapy  
Key exclusion criteria:  
 Infections associated with, or in close proximity to, a prosthetic device  
 Severe sepsis or refractory shock  
 Known or suspected bacteremia at time of screening  
 ABSSSI due to or associated with any of the following:  

Oritavancin diphosphate  Clinical Study Protocol MDCO-ORI-16-02 
The
 Medicines Company  
 
Confidential  4 
  Infections suspected or documented to be caused by Gram -negative pathogens (i.e., human or 
animal bites, injuries contaminated with fresh or salt water, external malignant otitis)  
 Wound infections (sur gical or traumatic) and abscesses with only Gram -negative pathogens  
 Diabetic foot infections (infection extending distal to the malleoli in a subject with diabetes 
mellitus and peripheral neuropathy and/or vascular insufficiency or any ulceration of their  foot)  
 Concomitant infection at another site not including a secondary ABSSSI lesion (e.g., septic 
arthritis, endocarditis, osteomyelitis)  
 Infected burns  
 A primary infection secondary to a pre -existing skin disease with associated inflammatory 
changes suc h as atopic dermatitis, eczema , or hidradenitis suppurativa  
 Decubitus or chronic skin ulcer, or ischemic ulcer due to peripheral vascular disease (arterial or 
venous)  
 Any evolving necrotizing process (i.e. , necrotizing fasciitis), gangrene or infection su spected or 
proven to be caused by Clostridium species (e.g., crepitance on examination of the ABSSSI site 
and/or surrounding tissue(s) or radiographic evidence of subcutaneous gas in proximity to the 
infection)  
 Infections known to be caused by a Gram -posit ive organism with a vancomycin minimum 
inhibitory concentration (MIC) >2  μg/mL or clinically failing prior therapy with glycopeptides  
 Catheter site infections  
 Treatment with investigational medicinal product within 30 days or 5 half -lives, whichever is 
longer, before enrollment and for the duration of the study . 
 Prior exposure to oritavancin alone or in combination with another product . 
Test Drug , Dose and Mode o f Administration :  The investigational drug oritavancin diphosphate (oritavancin) 
will be administered intravenously to all subjects. The dose is made up of three single -use vials, each containing 
400 mg of oritavancin and the inactive component mannitol. At the time of use, each vial should be reconstituted 
by adding 40  mL of Sterile Water for  Injection, United States Pharmacopeia (USP). After reconstitution, 
oritavancin should be further diluted in approximately 1000  mL of 5% Dextrose  Water  Injection (D5W).  
On Day 1 of the study, subjects will be administered a single 1200 -mg IV dose of oritav ancin in 1000  mL D5 W. 
On Day 8, an additional 1200 -mg IV dose of oritavancin in 1000  mL D5W or placebo (D5W) will be 
administered. Oritavancin or placebo must be infused over 3 hours.  No other material or diluent may be 
substituted or concomitantly infused through the same IV line.  
Duration of Treatment : The study will consist  of four p eriods: Screening (≤24 hours prior to Day 1), Pre -Dose 
(Day 1), Treatment (Day 1, Day 8), and Follow -up (Day 15, Day 22).   
Reference Therapy, Dose and Mode of Administration :  Five subjects will be administered a placebo 
(1000  mL of D5W) infused over 3 h ours for the second dose.  
Criteria for Evaluation :   
 
Oritavancin diphosphate  Clinical Study Protocol MDCO-ORI-16-02 
The
 Medicines Company  
 
Confidential  5 
 Primary outcome:  
 Safety of the administration of oritavancin in subjects will be assessed according to vital signs, 
laboratory abnormalities, and the incidence of adverse events (AEs) and serious adverse events 
(SAEs).  
Secondary outcome :  
 Clinical cure, as an assessment of efficacy, determined by the investigator at Day 8. 
Exploratory outcome : 
 Antibody development following a single dose and multiple doses of oritavancin administration.  
Clinical evaluation time points : 
 Assessment of safety (AEs) through  Day 22  
 Post-therapy efficacy evaluation at Day 8 
Efficacy :  Clinical cure  
Safety :  AEs, vital signs, clinical laboratory  assessments  
Statistical Methods :  Approximately 20 ABSSSI subjects will be enrolled.  All 20 subjects will receive a single 
dose of oritavancin on Day 1, 15 subjects will receive a second 1200 -mg dose of oritavancin and 5 subjects will 
receive a placebo infusion  on Day  8.  
Sample size :  Twenty ABSSSI subjects were added to obt ain safety information and to assess the potential for 
antibody production related to oritavancin administration.  
Analysis population : The subject populations are defined as follows:  
Intent -to-Treat (ITT) Population: The ITT population will include all subjects screened and randomized.  
Safety Population: All subjects dosed with IV oritavancin. The safety population will be the primary population 
for all the safety analyses.  
Descriptive  statistics will be provided for demographic, baseline characteristics, medical history, prior and 
concomitant medications. Descriptive statistics include means, medians, standard deviations and ranges for 
continuous variables, as well as frequency and per centage for categorical variables. Summary tables and listings 
of safety data, including AEs, laboratory results (direct and indirect antiglobulin , immunoglobulin panel, 
oritavancin antibody assay) and vital signs will be provided for the Safety Population . Summaries of clinical cure 
as assessed by the investigator at Day 8 will be provided for the ITT Population.  
 
 
 
Oritavancin diphosphate  Clinical Study Protocol MDCO-ORI-16-02 
The
 Medicines Company  
 
Confidential  6 
 TA
BLE OF CONTENTS 
1. I NTRODUCTION ......................................................................................................13 
1.1. B ackground .................................................................................................................13 
1.2. Or itavancin (ORBACTIV™) .....................................................................................13 
1.2.1. Nonc linical Studies .....................................................................................................13 
1.2.2. C linical Pharmacology ................................................................................................13 
1.2.3. C linical Studies ...........................................................................................................14 
1.2.4. Know n and Potential Risks and Benefits....................................................................15 
1.3. S tudy Rationale ...........................................................................................................17 
2. TR IAL OBJECTIVES AND PURPOSE ....................................................................18 
2.1. P rimary Objective .......................................................................................................18 
3. TR IAL DESIGN .........................................................................................................19 
3.1. T ype/Design of Trial ...................................................................................................19 
3.2. P rimary Endpoint ........................................................................................................19 
3.3. S econdary Endpoint ....................................................................................................19 
3.4. Ex ploratory Endpoint ..................................................................................................19 
3.5. Me asures to Minimize/Avoid Bias .............................................................................20 
3.5.1. B linded Study Where Pharmacist is Unblinded .........................................................20 
4. S UBJECT POPULATION .........................................................................................21 
4.1. Numbe r of Subjects ....................................................................................................21 
4.2. I nclusion Criteria ........................................................................................................21 
4.3. Ex clusion Criteria .......................................................................................................21 
4.4. W ithdrawal Criteria ....................................................................................................22 
5. TREATMEN T OF SUBJECTS ..................................................................................24 
5.1. S tudy Medications ......................................................................................................24 
5.1.1. Or itavancin .................................................................................................................24 
5.1.2. P lacebo ........................................................................................................................24 
5.1.3. P ackaging and Labeling ..............................................................................................24 
5.1.4. S torage ........................................................................................................................24 
5.1.5. Ac countability .............................................................................................................25 
5.1.6. P roduct Complaints ....................................................................................................25 
5.2. C oncomitant Medications ...........................................................................................26 
Oritavancin diphosphate  Clinical Study Protocol MDCO-ORI-16-02 
The
 Medicines Company  
 
Confidential  7 
 5.2.1. P rohibited Concomitant Medications .........................................................................26 
5.2.2. P ermitted Concomitant Medication(s) ........................................................................26 
5.3. Me dical Management Guidelines ...............................................................................26 
5.3.1. Gr am-negative pathogen ABSSSI infections .............................................................27 
5.4. R estrictions .................................................................................................................27 
5.5. B linding ......................................................................................................................27 
5.5.1. Me thod and Maintenance of Blinding ........................................................................27 
5.6. Unblindi ng ..................................................................................................................27 
6. S CHEDULE AND SEQUENCE OF PROCEDURES ...............................................28 
6.1. S chedule of Events/Assessments ................................................................................29 
6.2. Ge neral Conduct of the Trial ......................................................................................31 
6.3. S creening Period (24 hours Prior to Day 1) ................................................................31 
6.4. Da y 1 Pre-dose ............................................................................................................31 
6.5. Tr eatment Period ........................................................................................................32 
6.5.1. Da y 1 ...........................................................................................................................32 
6.5.2. Da y 8 Pre-dose ............................................................................................................32 
6.5.3. Da y 8 Post-dose ..........................................................................................................32 
6.6. F ollow-up Period ........................................................................................................33 
6.6.1. Da y 15 (±2 days) ........................................................................................................33 
6.6.2. Da y 22 (±2 days) ........................................................................................................33 
7. P ROTOCOL ASSESSMENTS ..................................................................................34 
7.1. Asse ssment of Safety ..................................................................................................34 
7.1.1. Adve rse events ............................................................................................................34 
7.1.2. P hysical examinations ................................................................................................34 
7.1.3. Vital si gns ...................................................................................................................34 
7.1.4. L aboratory assessments ..............................................................................................34 
7.2. Asse ssment of Efficacy ...............................................................................................35 
7.3. Asse ssment of Pharmacokinetics ................................................................................35 
8. AD VERSE EVENTS..................................................................................................37 
8.1. De finitions ..................................................................................................................37 
8.1.1. Adve rse Event .............................................................................................................37 
8.1.1.1.
 AE Severity .................................................................................................................37 
Oritavancin diphosphate  Clinical Study Protocol MDCO-ORI-16-02 
The
 Medicines Company  
 
Confidential  8 
 8.1.1.2.
 Study Drug Causality ..................................................................................................37 
8.1.2. S erious Adverse Event ................................................................................................38 
8.1.3. Me dication Errors .......................................................................................................38 
8.1.4. Adve rse Event of Special Interest (AESIs) ................................................................39 
8.2. P rocedure for Non-Serious Adverse Event Recording ...............................................39 
8.3. P rocedure for Serious Adverse Event Reporting ........................................................39 
8.4. P rocedure for Medication Error Reporting For Study Products .................................40 
8.5. P rocedure For Reporting Adverse Events Of Special Interest (AESIs) .....................40 
8.6. P rocedure For Reporting Pregnancies ........................................................................40 
8.7. Ong oing Safety Monitoring and Stopping Rules ........................................................41 
8.8. P rocedure For Reporting Special Situations ...............................................................41 
9. DA TA COLLECTION ...............................................................................................42 
10. S TATISTICAL PLAN................................................................................................43 
10.1. S ample Size ................................................................................................................43 
10.2. R andomization ............................................................................................................43 
10.3. Ge neral Statistical Considerations and Definitions ....................................................43 
10.3.1.
 General Statistical Methods ........................................................................................43 
10.3.2.
 Analysis Population ....................................................................................................43 
10.3.2.1.
 Intent- to-Treat (ITT) Population .................................................................................43 
10.3.2.2.
 Safety Population ........................................................................................................43 
10.3.3.
 Analysis Windows and Baseline ................................................................................43 
10.3.4.
 Missing Data Handling ...............................................................................................44 
10.4. S tatistical Analyses .....................................................................................................44 
10.4.1.
 Demographic and Background Characteristics ..........................................................44 
10.4.2.
 Prior and Concomitant Medications ...........................................................................44 
10.4.3.
 Safety Analysis ................................ ...........................................................................44 
10.4.3.1. Adve rse Events ...........................................................................................................44 
10.4.3.2.
 Clinical Safety Laboratory Tests ................................................................................44 
10.4.3.3.
 Vital Signs ..................................................................................................................45 
11. REC ORDS RETENTION ..........................................................................................46 
12. QU ALITY CONTROL AND QUALITY ASSURANCE .........................................47 
12.1. Moni toring ..................................................................................................................47 
Oritavancin diphosphate  Clinical Study Protocol MDCO-ORI-16-02 
The
 Medicines Company  
 
Confidential  9 
 12.2. Auditi ng ......................................................................................................................47 
12.3. P rotocol Deviations ....................................................................................................47 
13. ETH ICS AND RESPONSIBILITY ............................................................................49 
13.1. I nformed Consent .......................................................................................................49 
13.2. I nstitutional Review Board/Ethics Committee ...........................................................49 
14. C ONFIDENTIALITY ................................................................................................50 
15. I NVESTIGATOR AGREEME NT .............................................................................51 
16. R EFERENCES ...........................................................................................................52 
16.1. P ublications .................................................................................................................52 
Oritavancin diphosphate  Clinical Study Protocol MDCO-ORI-16-02 
The
 Medicines Company  
 
Confidential  10 
  
LI
ST OF ABBREVIATIONS 
ABSSSI  acute bacterial skin and skin structure infection  
AE adverse event  
AESI (s) Adverse Event of Special Interest(s)  
AIDS  Acquired Immune Deficiency Syndrome  
ANC  absolute neutrophil count  
AUC  area under the plasma concentration time curve  
AUC 0-24 area under the drug concentration -time curve from time zero to 24 
hours  
AUC 0-∞ area under the concentration -time curve from zero to infinity  
BMI  body mass index  
CD4  cluster of differentiation 4  
Cmax maximum plasma concentration  
CS clinically significant  
CV coefficient of variation  
DAT  direct antiglobulin  testing  
D5W  5% dextrose in water  
EC Ethics Committee  
eCRF  Electronic Case Report Form  
EDC  electronic data capture  
ESR erythrocyte sedimentation rate  
FDA  Food and Drug Administration  
GCP  Good Clinical Practice  
h hour 
Oritavancin diphosphate  Clinical Study Protocol MDCO-ORI-16-02 
The
 Medicines Company  
 
Confidential  11 
 HEENT  head, eyes, ears, nose, throat  
HIV human immunodeficiency virus  
ICH Internatio nal Conference on Harmonisation  
IAT indirect antiglobulin  testing  
ID Identification number  
IgA immunoglobulin A  
IgE immunoglobulin E  
IgG immunoglobulin G  
IgM immunoglobulin M  
IMP Investigational Medicinal Product  
IRB Institutional Review Board  
ITT intent -to-treat 
IV intravenous  
kg kilograms(s)  
MDCO  The Medicines Company  
MedDRA  Medical Dictionary for Regulatory Activities  
mg milligram(s)  
MI myocardial infarction  
MIC  minimum inhibitory concentration  
mL milliliter(s)  
mm millimeter(s)  
min minute(s)  
MRSA  methicillin -resistant Staphylococcus aureus  
No. number  
Oritavancin diphosphate  Clinical Study Protocol MDCO-ORI-16-02 
The
 Medicines Company  
 
Confidential  12 
 OTC  over-the-counter  
PK pharmacokinetic  
Q1 first quartile  
Q3 third quartile  
s second(s)  
SAE (s) serious adverse event (s) 
SAP statistical analysis plan  
SD standard deviation  
SOC  standard of care  
TEAE  treatment -emergent adverse event  
t½  half-life 
t½,α half-life for the alpha phase  
t½,β half-life for the beta phase  
t½,γ half-life for the gamma phase  
US United States  
USP United States Pharmacopeia  
USPI  United States Package Insert  
Vss  steady -state volume of distribution  
WHO  World Health Organization  
y years(s)  
 
 
Oritavancin diphosphate  Clinical Study Protocol MDCO-ORI-16-02 
The
 Medicines Company  
 
Confidential  13 
 1. I
NTRODUCTION 
This protocol describes a multicenter, double-blind, randomized study to evaluate the safety of 
two 1200-
mg intravenous ( IV) doses of Orbactiv™ for the treatment of subjects with an acute 
ba
cterial skin and skin structure infection (ABSSSI). 
This study will be conducted in compliance with Good Clinical Practices (GCP) including the 
Declaration of Helsinki and all applicable regulatory requirements. 
1.1. Background 
ABSSSIs are common infections that include cellulitis, major cutaneous abscesses, and wound 
infections.  ABSSSIs are inflammatory microbial invasions of the epidermis, dermis, and 
subc
utaneous tissues [ Dryden, 2009 ].  These infections are frequently caused by Gram-positive 
ba
cteria including methicillin-susceptible Staphylococcus aureus , methicillin-resistant S. aureus  
(MRSA), Streptococcus pyogenes , and other β-hemolytic streptococcal species and enterococci.  
The clinical complications of improperly treated or untreated ABSSSIs may include local 
expansion and spread, secondary bacteremia with potential for distant metastatic foci of 
infection, and systemic effects of bacterial infection. 
1.2. Oritavancin (ORBACTIV™) 
Oritavancin is a novel semi-synthetic, lipoglycopeptide antibiotic that has three mechanisms of 
action: 1) inhibition of the transglycosylation (polymerization) step of cell wall biosynthesis by 
binding to the stem peptide of peptidoglycan precursors; 2) inhibition of the transpeptidation 
(crosslinking) step of cell wall biosynthesis by binding to the peptide bridging segments of the 
cell wall; and 3) disruption of bacterial membrane integrity, leading to depolarization, 
permeabilization, and rapid cell death.  These multiple mechanisms contribute to the rapid, 
c
oncentration-dependent bactericidal activity of oritavancin. 
Oritavancin has been approved by the Food and Drug Administration (FDA) for the treatment of 
adult subjects with ABSSSIs caused or suspected to be caused by susceptible isolates of 
designated Gram-positive microorganisms including MRSA [ ORB ACTIV™ Package Insert 
2016].   
1.2.1. Nonclin ical Studies  
Oritavancin has been extensively studied pre-clinically.  The results from the safety, toxicology, 
pharmacokinetic (PK), and pharmacodynamic studies demonstrate that oritavancin does not 
induce any biologically significant toxicity.  An overview of relevant nonclinical study results is 
presented in the Investigator’s Brochure [ Oritavancin Investigator’s Brochure Version 10 ] .   
1.2.2. Clin ical Pharmacology 
The PK  of a single 1200-mg dose of oritavancin in ABSSSI subjects were determined from 
population PK analysis of pooled data from 297 adult subjects and are presented in Table 1.  At 
stea
dy state, oritavancin exhibits linear PK at a dose up to 1200 mg.  The mean population-
pre
dicted oritavancin concentration-time profile displays a multi-exponential decline and a lon g 
Oritavancin diphosphate  Clinical Study Protocol MDCO-ORI-16-02 
The
 Medicines Company  
 
Confidential  14 
 ter
minal half-life (t½) of 245 hours.  Normal healthy volunteers administered a single 1200-mg 
dose
 of oritavancin experience higher oritavancin exposure when compared to subjects; mean 
Cmax was approximately 25% higher in healthy volunteers, and AUC 0 -∞ was approximately 40% 
hig
her in healthy volunteers when compared to subjects. 
T
able 1: Mean Pharmacokinetic Parameters for ABSSSI Subjects Receiving a Single 
1200 -mg Dose (n = 297) 
Parameter  Mean  (CV%)  
Vss (L) 97.8 (56.4%)  
Cmax (μg/mL)  138 (23.0%)  
AUC 0-24 (μg•h/mL)  1110  (33.9%)  
AUC 0-72 (μg•h/mL)  1530  (36.9)  
AUC 0-∞ (μg•h/mL)  2800  (28.6%)  
T1/2,α (h) 2.29 (49.8%)  
T1/2,β (h) 13.4 (10.5%)  
T1/2,γ (h) 245 (14.9%)  
Vss, Steady-state volume of distribution; C max, Maximum plasma concentration; AUC 0-24, Area under the plasma 
concentration-time curve from time zero to 24 hours; AUC 0-∞, Area under the plasma concentration time curve from 
time zero to infinity; T ½,α, Half-life for the alpha phase, T ½,β, Half-life for the beta phase; T ½,γ, Half-life for the 
gamma phase; CV%, Percent coefficient of variation. 
1.2.3. Clin ical Studies 
An extensive clinical development program has been conducted to evaluate the safety and 
effectiveness of oritavancin comprising 4 completed Phase III studies, 4 Phase II studies, 14 
Phase I studies in healthy subjects, and one Phase I study in both healthy and hepatically 
impaired subjects.  Throughout the completed studies, IV oritavancin was administered to 3042 
indi
viduals (2632 subjects and 410 healthy subjects) including 1075 adult subjects with ABSSSI 
treated with a 1200-mg single-dose regimen. [ Oritavancin Investigator’s Brochure Version 10 ]. 
Efficacy and safety findings of the intended treatment dose in adult subjects with ABSSSI are 
summarized below:  
Efficacy 
The results from SOLO I and SOLO II in 1959 adult subjects demonstrated that a single 1200-
mg IV dose of oritavancin was clinically non-inferior to 7 to 10 days of IV vancomycin (1 g or 
15 mg/kg twice daily) using a pre-specified non-inferiority margin of 10% for both early clinical 
re
sponse and clinical cure at post-therapy evaluation.  The subject population was representative 
of A
BSSSIs with S. aureus  the common causative pathogen isolated; a large subset of subjects 
(N
=405) had documented MRSA infections.  Efficacy in MRSA subjects was similar to that 
obse
rved in the overall population for all endpoints. 
Safety 
The SOLO I and SOLO II studies demonstrated that a single 1200-mg IV dose of oritavancin 
was well tolerated and had a similar safety profile to 7 to 10 days of IV vancomycin treatment as 
demonstrated by the similar frequency and nature of treatment-emergent adverse events 
Oritavancin diphosphate Clinical Study Protocol MDCO-ORI-16 -02 
The Medicines Company 
Confidential 15 (T
EAEs), serious adverse events (SAEs), and adverse events (AEs) leading to discontinuation 
reported by subject s. 
1.2.4.  Known and Potential Risks and Benefits 
SINGLE DOSE 
Twenty three clinical trials, including 4 Phase III, 4 Phase II, and 15 Phase I studi es have been 
completed to date in which 3042 subjects were exposed to oritavanc in.  The most common 
adverse events (>3%) by preferred term in either treatme nt group, in the SOLO I or SOL O II 
studies were nausea, headache, vomiting, cellulitis, diarrhea, constipation, infusion site 
extravasation, pyrexia and pruritus, as outlined in Table 2. 
Table 2: Adverse Events that Occurred in ≥3% of Subjects in the Oritavancin 
Treat
ment Group (Safety Population) 
SOLO Pool  
Preferred Term  Oritavancin  
(N=976)  
n (%)  Vancomycin  
(N=983)  
n (%)  
Nausea  97 (9.9%)  103 (10.5%)  
Headache  69 (7.1%)  66 (6.7%)  
Vomiting  45 (4.6%)  46 (4.7%)  
Cellulitis  37 (3.8%)  32 (3.3%)  
Diarrhea  36 (3.7%)  32 (3.3%)  
Constipation  33 (3.4%)  38 (3.9%)  
Infusion site extravasation  
Pyrexia  
Pruritus  33 (3.4%)  
30 (3.1%) 
29 (3.0%)  33 (3.4%) 
31 (3.2%)  
73 (7.4%)  
Serious hypersensitivity reactions have been reported with the use of oritavancin which could 
possibly have cross-sensitivity with hypersensitivity to glycopeptide drugs (e.g. vancomycin). 
In the Phase III ABSSSI clinical trials, the median onset of hypersensitivity reactions in 
oritavancin-treated subjects was 1.2 days and the median duration of these reactions was 2.4 
days. 
Infusion-related reactions or anaphylactoid reactions have been reported with oritavancin 
including pruritus, urticaria, or flushing.   
MULTIPLE DOSE  
In MDCO-ORI-15-02, a Phase I clinical study, 10 healthy volunteers received two doses of 
1200  mg oritavancin given 14 days apart.  Seven of the 10 subjects receiving oritavancin 
re
ported AEs during the second infusion with 5 prematurely discontinuing dosing during the 
second infusion.  The predominant symptoms in the 7 subjects who experienced AEs were 
Oritavancin diphosphate  Clinical Study Protocol MDCO-ORI-16-02 
The
 Medicines Company  
 
Confidential  16 
 musculoskele
tal complaints (e.g., lower back pain) as well as gastrointestinal complaints 
(nausea, vomiting).  Fever or rash was not reported in any subject.  Symptoms developed in all 7 
subjec
ts within 30 to 90 minutes from the start of the infusion and resolved in all within a few 
hours of study drug discontinuation.  None of the AEs experienced were deemed SAEs by the 
investi
gator, but in aggregate were considered by The Medicines Company (MDCO) as an 
im
portant medical finding warranting of an IND Safety Report.  Further dosing in this study was 
volunt
arily terminated by MDCO in order to investigate further the observed AEs during the 
second dose.  The key findings from these investigations are presented below. 
 
 No c orrelation between immunoglobulin levels and subjects experiencing an AE in 
MDCO-ORI-15-02 
 No pa ttern of cytokine/chemokine response in oritavancin-stimulated peripheral 
blood mononuclear cells from subjects with symptoms from MDCO-ORI- 15-02 
 No l ymphoproliferative response in oritavancin-stimulated peripheral blood 
mononuclear cells from subjects with symptoms from MDCO-ORI-15-02 
 No he althy subjects have developed a positive direct test for hemagglutination in the 
presence of drug testing and no subjects met clinical criteria for drug-induced 
autoimmune hemolytic anemia.  In ex vivo testing of healthy subject plasma samples, 
administration of oritavancin (and development of a positive indirect antiglobulin test 
[
IAT]) appears to be associated with a weakly positive indirect test for 
hemagglutination in the presence of drug. 
 Admini stration of oritavancin to healthy subjects in 2 separate studies (MDCO-ORI-
15-02 and MDCO-ORI- 15- 01) was associated with development of a positive IAT in 
the majority of oritavancin-treated subjects; the IAT result reversed to negative in all 
subj
ects within 30 to 60 days. 
 None  of the 15 subjects with ABSS SI infections treated with a single 1200-mg dose 
of or
itavancin in the ongoing Study MDCO-ORI-14-03 (Warfarin Study in ABSSSI 
S
ubjects) in whom direct antiglobulin testing (DAT) or IAT was performed for up to 
14 da
ys developed a positive DAT or IAT.  
 R esults of recent post-marketing surveillance revealed 15 reports of subjects who 
received multiple doses of oritavancin.  Two reports described the onset of back pain 
during
 the second infusion of oritavancin.  In one report, the infusion was stopped and 
the subje
ct was treated for symptoms; the subject was able to complete the infusion at 
a slower rate without further complications.  In the second report, the subject was 
treated for symptoms at the end of the dose. 
In summary, currently available data show that, in some healthy volunteer subjects, receipt of 
oritavancin was associated with a positive IAT (also called indirect Coombs test), which resolved 
ove
r time, and a weakly positive indirect test for hemagglutination in the presence of drug with 
ex vivo testing .  There have been no positive DATs and no similar AEs reported following a 
sing
le dose.  There is no evidence of autoimmune hemolytic anemia or definitive immune-related 
sequelae.  
In view of the difference in the rate of development of positive IAT between healthy 
Oritavancin diphosphate  Clinical Study Protocol MDCO-ORI-16-02 
The
 Medicines Company  
 
Confidential  17 
 subj
ects and infected subjects, we believe that it is most appropriate to further evaluate multiple-
dose administration in patients with ABSSSI infections rather than in healthy volunteer subjects.  
S
ubjects with ABSSSIs are to be enrolled to collect additional data on DAT and IAT, and to 
a
ssess the safety of a second dose of oritavancin in these subjects in a controlled setting. 
A complete description of relevant risks of oritavancin can be found in the Investigator’s 
Brochure [ Oritavancin Investigator’s Brochure Version 10 ] and the United States Package Insert 
(USPI).  More information regarding the events in Study MDCO-ORI-15-02 can be found in the 
Aggr
egate Report (dated August 26, 2015) of Infusion-Related Reactions Following the Second 
Infusion in Study MDCO-ORI-15-02 [ A ggregate Report, 2015 ] and the subsequent follow up 
information dated July 22, 2016 [ F ollow-up  Report, 2016 ] . 
1.3. Study Rationale  
Clinical studies in adult subjects with ABSSSI have demonstrated that a single 1200-mg IV dose 
of oritavancin was clinically non-inferior, well tolerated, and had a similar safety profile to 7 to 
10 days of IV vancomycin treatment (See Section 1.2.3  for additional details).  
The
 rationale for selecting the 1200-mg IV dose of oritavancin is described in Section 1.2.2.  The 
1200-mg dose of oritavancin is the United States (US) approved therapeutic dose. 
S
ubjects with ABSSSI will be enrolled in this study to obtain safety information of two 1200-mg 
I
V infusions of oritavancin when administered one week apart.   
S
tudy Population 
The study population will comprise of subjects who are at least 18 years of age with an ABSSSI 
suspected or confirmed to be caused by gram-positive pathogens.  An ABSSSI includes the 
following
 infections: wound infections, cellulitis/erysipelas, and major cutaneous abscess.  
Oritavancin diphosphate  Clinical Study Protocol MDCO-ORI-16-02 
The
 Medicines Company  
 
Confidential  18 
 2. TR
IAL OBJECTIVES AND PURPOSE 
The purpose of this study is to evaluate the safety and tolerability of two 1200-mg IV infusions 
of oritavancin when administered one week apart. 
2.1. Primary Objective 
Assess the safety and tolerability of two 1200-mg IV infusions of oritavancin when administered 
one week apart in subjects with ABSSSI.  
 
Oritavancin diphosphate  Clinical Study Protocol MDCO-ORI-16-02 
The
 Medicines Company  
 
Confidential  19 
 3. TR
IAL DESIGN 
3.1. Type/Design of Trial 
This will be a Phase IV, randomized, double-blind trial in subjects with ABSSSI.  
Appr
oximately 20 subjects will be enrolled at approximately 5 centers in the US.  Informed 
c
onsent will be obtained from subjects before the initiation of any study-specific procedures.  
Eligible subjects will be randomized to receive either two doses of oritavancin one week apart or 
one dose of oritavancin and a single dose of placebo one week apart in a 3:1 ratio.  
The
 study will consist of four periods: Screening (≤24 hours prior to Day 1), Pre-Dose (Day 1), 
Treatment (Day 1, Day 8), and Follow-up (Day 15, Day 22).  
S
afety assessments will include vital signs, laboratory abnormalities, and the incidence of AEs 
a
nd SAEs (see Section 6 for  assessment details).  
The
 maximum duration of a subject’s participation in this study is approximately 22 days after 
the f
irst administration of oritavancin.  
The Sponsor will collect reticulocyte count, complete blood count, and manual blood smears pre- 
a
nd post- the second infusion of oritavancin.  Infusion-related reactions will be considered an AE 
of Spec
ial Interest within the protocol and will be followed until resolution.  This designation 
will require that any reports (whether serious or non-serious) will be submitted to the Sponsor 
within 24 hours, along with a narrative and all necessary information to complete a 
CIOMS/MedWatch form, ensuring that complete and detailed information is obtained on the 
event.  Furthermore, any clinically significant lab data or adverse events occurring after the 
second dose will be required to be entered in the database within 24 hours in order to facilitate 
the Sponsor’s ongoing review of safety data. The Sponsor will be conducting ongoing review of 
the safety data within Study MDCO-ORI-16-02 (AEs, vital signs and labs) 
3
.2. Primary Endpoint 
The primary endpoint of this trial is :  
 S afety of the administration of oritavancin in subjects will be assessed according to 
vital signs, laboratory abnormalities, and the incidence of AEs and SAEs. 
3.3. Secondary Endpoint 
The secondary endpoint of this trial is: 
 C linical cure determined by the investigator at the Day 8 visit. 
3
.4. Exploratory Endpoint 
The exploratory endpoint of this trial is: 
 Additi onal information collected will include (a) potential for antiglobulin 
development (direct and indirect) (b) change or increase in immunoglobulin profile 
and (c) development of drug-specific antibody in response to two 1200mg IV 
infusions of oritavancin.   
Oritavancin diphosphate  Clinical Study Protocol MDCO-ORI-16-02 
The
 Medicines Company  
 
Confidential  20 
 3
.5. Measures to Minimize/Avoid Bias 
3.5.1. B linded Study Where Pharmacist is Unblinded 
This is a double-blind study design to minimize bias on study outcomes potentially introduced by 
the study procedures.  The placebo subjects also serve as a control for external factors that may 
exist at the time subjects are enrolled.  
Subjects will be given a subject identification (ID) number sequentially according to the date and 
time when subjects sign the informed consent (screening number).  The unblinded pharmacist 
will match the subject ID with the randomization schedule, which assigns treatment sequence 
based on 3:1 ratio.  The oritavancin and placebo infusion arms will be double-blind; all study 
staff will be blinded to the treatment with the exception of the unblinded pharmacist.   
The blinding of IV treatment assignment will be maintained until database lock.   
Oritavancin diphosphate  Clinical Study Protocol MDCO-ORI-16-02 
The
 Medicines Company  
 
Confidential  21 
 4. SU
BJECT POPULATION 
4.1. Number of Subjects  
Approximately 20 subjects will be studied at 1-2 centers located in the US. 
4
.2. Inclusion Criteria 
Subjects may be included in the study if they meet all of the following criteria: 
1. Ma les or females ≥18 years old 
2. Dia gnosis of ABSSSI (wound infections, Cellulitis/erysipelas, or cutaneous abscess) 
suspected or confirmed to be caused by a Gram-positive pathogen requiring IV therapy 
3. Able  to give informed consent and willing to comply with all required study procedures 
4.3. Exclusion Criteria 
Subjects will be excluded from the study if any of the following exclusion criteria apply prior to 
randomization: 
1. I nfections associated with, or in close proximity to, a prosthetic device 
2. S evere sepsis or refractory shock 
3. Know n or suspected bacteremia at time of screening  
4. AB SSSI due to or associated with any of the following: 
a. Infections suspected or documented to be caused by Gram-negative pathogens (i.e., 
human or animal bites, injuries contaminated with fresh or salt water, external 
malignant otitis) 
b. W ound infections (surgical or traumatic) and abscesses with only Gram-negative 
pathogens  
c. Diabetic foot infections (infection extending distal to the malleoli in a subject with 
diabetes mellitus and peripheral neuropathy and/or vascular insufficiency or any 
ulceration of their foot) 
d. Concomitant infection at another site not including a secondary ABSSSI lesion (e.g., 
septic arthritis, endocarditis, osteomyelitis) 
e. Infected burns 
f. A primary infection secondary to a pre-existing skin disease with associated 
infla
mmatory changes such as atopic dermatitis, eczema, or hidradenitis suppurativa 
g. Decubitus or chronic skin ulcer, or ischemic ulcer due to peripheral vascular disease 
(arterial or venou s) 
h. An y evolving necrotizing process (i.e., necrotizing fasciitis), gangrene, or infection 
suspected or proven to be caused by Clostridium  species (e.g., crepitance on 
e
xamination of the ABSSSI site and/or surrounding tissue(s) or radiographic evidence 
of subcutaneous gas in proximity to the infection) 
i. Infections known to be caused by a Gram-positive organism with a vancomycin 
minimum inhibitory concentration (MIC) >2 μg/mL or clinically failing prior therapy 
with g
lycopeptides 
Oritavancin diphosphate  Clinical Study Protocol MDCO-ORI-16-02 
The
 Medicines Company  
 
Confidential  22 
 j. C
atheter site infections 
5. C urrently receiving chronic systemic immunosuppressive therapy such as chemotherapy 
or prednisone (prednisone at non- immunosuppressive doses of ≤15 mg/day is permitted) 
6. S ubjects who are likely to need treatment with IV unfractionated heparin sodium within 
48 hours after oritavancin administration 
7. L ast known cluster of differentiation 4 (CD4) count <200 cells/mm3 in subjects with 
known huma
n immunodeficiency virus (HIV)/acquired immune deficiency syndrome 
(AIDS) 
8. Ne utropenia with absolute neutrophil count (ANC) <500 cells/mm3 
9. S ignificant or life-threatening condition (e.g., endocarditis) that would confound or 
interfere with the assessment of safety 
10. Women who are pregnant or nursing, or who are of childbearing potential and unwilling 
to use at least 2 acceptable methods of birth control: (e.g., prescription oral 
contraceptives, contraceptive injections, contraceptive patch, intrauterine device, barrier 
method(s) or male partner sterilization).  Women ≥2 years postmenopausal or surgically 
ster
ile are exempt from this exclusion 
11. History of immune-related hypersensitivity reaction to glycopeptides (such as 
vancomycin, televancin, daptomycin, or dalbavancin) or any of their excipients.  Note: 
subj
ects who have had histamine-like infusion reactions to a glycopeptide are not 
excluded 
12. Subjects unwilling to forego blood and/or blood product donation for at least 1 month 
from initiation of oritavancin dose 
13. Treatment with investigational medicinal product within 30 days or 5 half-lives, 
whichever is longer, before enrollment and for the duration of the study 
14. Investigational device present, or removed within 30 days before enrollment, or presence 
of device-related infection  
15. Subjects who the investigator considers unlikely to adhere to the protocol, comply with 
oritavancin administration, or complete the clinical study (e.g., unlikely to survive 90 
days from initiation of oritavancin dosing) 
16. Prior exposure to oritavancin alone or in combination with another product. 
Subjects excluded for any of the above reasons may only be re- screened for participation after 
favorable discussion with Sponsor and principal investigator. 
4.4. Withdrawal Criteria 
All subjects have the right to withdraw at any point during treatment without prejudice.  The 
investigator can discontinue any subject at any time if medically necessary.  It will be 
documented whether or not each subject completed the clinical study.  If for any subject study 
treatment or observations were discontinued, the reason will be recorded and the Sponsor should 
Oritavancin diphosphate  Clinical Study Protocol MDCO-ORI-16-02 
The
 Medicines Company  
 
Confidential  23 
 be
 notified promptly.  Reasons that a subject may discontinue participation in a clinical study are 
c
onsidered to constitute one of the following: 
 Adve rse event(s) 
 De ath 
 W ithdrawal of consent by subject 
 P hysician decision 
 L ost to follow-up 
It is imperative to obtain complete safety follow-up information for all subjects whether or not 
the
y discontinue oritavancin.  All data collected up until the time of subject withdrawal is to be 
e
ntered into the eCRF.  In addition, every attempt should be made to collect follow-up 
information except for those subjects who specifically withdraw consent for release of such 
information.  All procedures and laboratory specimens or tests requested for evaluation 
following administration of the study drug should be carried out when possible whether or not a 
subject continues to receive treatment according the protocol.  
 
Oritavancin diphosphate  Clinical Study Protocol MDCO-ORI-16-02 
The
 Medicines Company  
 
Confidential  24 
 5. TR
EATMENT OF SUBJECTS 
5.1. Study Medications 
Subjects will receive either two IV doses of 1200 mg oritavancin one week apart or will receive 
a single dose of 1200 mg oritavancin and a placebo infusion one week apart.  Oritavancin will be 
pre
pared by the study pharmacist/designee. 
5.1.1. Orit avancin 
Oritavancin will be supplied as a lyophilized powder in single-use glass vials. Each vial will 
contain 400 mg of oritavancin.  
Three 400 m
g vials will be required for each subject receiving oritavancin.  At the time of use, 
eac
h vial will be reconstituted by adding 40 mL of Sterile Water for Injection, United States 
P
harmacopeia (USP), to each 400 mg vial of oritavancin.  Vials reconstituted in this manner will 
provide
 a 10 mg/mL solution.  After reconstitution, oritavancin should be further diluted in 5% 
dextrose
 in water (D5W) to provide a total volume of approximately 1000 mL.  Since the 
solub
ility of oritavancin is highly dependent upon pH, no other material or diluent may be 
substituted or concomitantly infused through the same IV line.  The IV line should be flushed 
with D5W
 before and after; saline must not be used since it may cause precipitation. 
Subjects will receive either one or two 1200 mg IV oritavancin doses in 1000 mL of D5W 
a
dministered as a constant rate IV infusion over 3 hours via a single dedicated peripheral IV line 
or a
 single dose of placebo, one week apart.  Oritavancin must be infused over 3 hours 
(6.7
 mg/minute) to reduce the potential for histamine like infusion reactions or phlebitis.   
5.1.2. P lacebo  
P
lacebo will be 1000 mL of D5W infused over 3 hours via a single dedicated peripheral IV line. 
5.1.3. P ackaging and Labeling  
Oritavancin will be provided by the Sponsor.  Infusion bags of D5W will be provided by the 
stud
y site pharmacy.  
Medication labels will comply with regulatory requirements.  The storage conditions for each 
medication provided will be described on the medication label. 
5.1.4.  Storage  
Oritavancin lyophilized powder should be stored in a secure cabinet or other enclosure at 
controlled room temperature (20°C to 25°C; 68°F to 77°F).  Diluted IV solution in an infusion 
ba
g should be used within 6 hours when stored at room temperature, or used within 12 hours 
when refrigerated at 2 to 8°C (36 to 46°F).  The combined storage time (reconstituted solution in 
the vial and diluted solution i
n the bag) and 3-hour infusion time should not exceed 6 hours at 
room temperature or 12 hours if refrigerated (see Pharmacy Manual).  Access should be strictly 
limited to the study pharmacists and their designees. 
Oritavancin diphosphate Clinical Study Protocol MDCO-ORI-16 -02 
The Medicines Company 
Confidential 25 5.1.5. Ac countability 
The investigator or designee must maintain an inventory record of all study medications received 
and administered to assure the regulatory authorities and the Sponsor that the drugs will not be 
dispense
d to any person who is not a subject under the terms and conditions set forth in this 
protocol.  Drug accountability forms and/or specific instructions can be found in the Pharmacy 
Ma
nual. 
The oritavancin supplied for use in this study is to be prescribed only by the principal 
investi
gator or designated sub-investigators and may not be used for any purpose other than that 
outlined in this protocol. 
During
 the study all used oritavancin containers (e.g., empty vials/bottles) will be kept until the 
monitor has reviewed the accountability records. 
All used and unused oritavancin supplied for this study will be destroyed on site once 
inventoried and the monitor ha
s reviewed the accountability records.  In the event that 
oritavancin needs to be returned for any other reason, the site will receive a written request 
listing drug lot number(s) to be returned and the reason for the return request. 
5.1.6. P roduct Complaints 
Sites are required to report any product complaints to MDCO immediately but no later than 24 
hours from the time of awareness, by phone or e-mail as follows: 
United States of America:  
Contact infor
mation for all other geographic areas: 
http://www.themedicinescompany.com/contact/global-medical-info  
Email:   
Product Complaint : Is defined as any written, electronic, or oral communication that alleges 
deficiencies related to the identity, durability, reliability, quality, safety, effectiveness or 
performance of a product, after it is released for distribution (EU DIR 2001/83/EC). (Derived 
from Ref US 21 CFR 211.198) 
There are two types of Product Complaints: Technical Quality Complaints : A report of 
dissatisfaction with product with regard to its efficacy, strength, integrity, purity, or quality; thus 
a potential failure to meet product specifications. Preference Complaints : A report of 
dissatisfaction with service, delivery, packaging or other preference. 
Technical Quality Complaint : A report of dissatisfaction with the product with regard to its 
efficacy, strength, integrity, purity, or quality; thus a potential failure to meet product 
specifications. Examples include:  
An indication that there is an unexpected physical change in the drug product such as
discoloration, change in shape of the drug product, presence of particulates or an y
other physical change that might indicate contamination, a manufacturing defect or
any other event that might indicate a compromise in product quality.
An indication that the content does not meet its labeled volume, count, etc.

Oritavancin diphosphate  Clinical Study Protocol MDCO-ORI-16-02 
The
 Medicines Company  
 
Confidential  26 
  An indica tion that there is an unexpected physical change in any part of the container 
(this includes the bottle, any part of the seal, the cap or the label).  
 An indica tion that the product is mislabeled.  
 An indica tion that there is an unexpected physical change of the product or container 
once the product is diluted or reconstituted (the container includes the vial, bag, IV 
line, syringe or any other item that is in contact with the product).  
 An indica tion that the product is falsified, tampered with, or adulterated.  
 An indica tion that the product did not meet its pharmacologic effect, i.e. lack of 
efficacy.  
 Me dical device incidents 
5.2. Concomitant Medications  
Any concomitant medications will be recorded in the electronic case report form (eCRF) 
according to the Schedule of Events. 
5.2.1. P rohibited Concomitant Medications 
There are no prohibited concomitant medications for this study. 
5.2.2.  Permitted Concomitant Medication(s) 
Subjects enrolled and treated with oritavancin may receive additional antibiotic therapy with 
Gram-negative coverage if necessary. 
5.3. Medical Management Guidelines 
Other interventions to optimize the care of subjects will be left to the discretion of the attending 
physician and investigator.  These include surgical/nonsurgical debridement of devitalized tissue, 
re
moval of prosthetic material, incision and drainage, suture removal, percutaneous aspiration, 
packing, dressings, or irrigation with normal saline to remove superficial slough, excess exudate 
or visible debris. Standard of care therapy (such as daily superficial debridements and dressing 
changes) are allowed.  
The investigator will be given guidance to stop, slow, or possibly even interrupt and restart an 
infusion should an infusion-related reaction occur. In addition, at the investigator’s discretion, 
patients who experience an infusion-related reaction may be given diphenhydramine or 
dexamethasone as treatment(s) for their symptoms.  In Study MDCO-ORI-15-02, all adverse 
e
vents observed that were associated with the second dose occurred within 30-90 minutes of the 
start of the 3 hour infusion and resolved within a few hours after the end of infusion. Therefore 
all infusions must be administered in the presence of a medically qualified team member and 
subj
ects will be required to remain in the administration setting for a minimum of 3 hours 
following the completion of the second IV infusion or until any AEs that occur are resolved or 
stable.  
If a subject is classified as a treatment failure by the investigator at any time, the subject may be 
a
dministered alternative antibiotic therapy according to clinical judgment. 
Oritavancin diphosphate  Clinical Study Protocol MDCO-ORI-16-02 
The
 Medicines Company  
 
Confidential  27 
  
5.3.1. G ram-negative pathogen ABSSSI infections 
Subjects enrolled and treated with oritavancin before culture results are available and found to 
have a Gram-negative pathogen may receive additional antibiotic therapy with Gram-negative 
coverage.  
5.4. Restrictions 
Subjects will be encouraged to continue their usual diet and level of activity, as dictated by their 
clinical condition.  Activities that would impact clinical outcome should be avoided during the 
stud
y period. 
5.5. Blinding 
5.5.1. M ethod and Maintenance of Blinding 
This is a randomized, double-blind study.  Subjects will be given a subject identification (ID) 
number sequentially according to the date and time when subjects sign the informed consent 
(sc
reening number).  The unblinded pharmacist will match the subject ID with the randomization 
schedule, which assigns treatment sequence based on 3:1 ratio.  The oritavancin and placebo 
infusion arms will be double-blind; all study staff will be blinded to the treatment with the 
exception of the unblinded pharmacist.   
5.6. Unblinding 
The blinding of IV treatment assignment will be maintained until database lock.  However, if a 
subject has a safety event that meets any of the protocol-defined stopping criteria, the subject’s 
treatment assignment will be unblinded after determining relatedness to the study drug.  The 
blind may also be broken for a specific subject only in the case where knowledge of the 
treatment assignment is deemed essential to subject safety or the occurrence of a SAE that, in the 
opinion of the investigator, cannot be adequately treated without knowing the identity of the 
study drug.  Any intentional or unintentional breaking of the blind should be immediately 
reported to the Sponsor.  
The principal investigator will be provided with instructions/envelopes for subject unblinding.   
Oritavancin diphosphate  Clinical Study Protocol MDCO-ORI-16-02 
The
 Medicines Company  
 
Confidential  28 
 6. SC
HEDULE AND SEQUENCE OF PROCEDURES 
The Schedule of Events/Assessments ( Table 3) summarizes the study assessments by time point.  
This s
tudy consists of 4 periods:  Screening, Pre-Dose, Treatment, and Follow-up.  
 The  Screening Period occurs <24 hours prior to administration of study drug on 
Da
y 1. 
 The  Pre-Dose Period occurs at Day 1 prior to oritavancin administration. 
 The  Treatment Period occurs from the time of study drug administration through 
Day 8 following study drug administration.  
 The  Follow-up Period occurs from the end of the Treatment Period through Day 22 
(
±2 days). 
The maximum duration of a subject’s participation in this study is approximately 22 days post 
fir
st administration of oritavancin. 
 
Oritavancin diphosphate                                                                    Clinical Study Protocol MDCO-ORI-16-02 
The
 Medicines Company  
 
Confidential                      29 
 6
.1. Schedule of Events/Assessments 
Table 3: Schedule of Events 
 
Study Procedures  Screening  Pre-Dose  Post -Dose  Pre-Dose  Post -Dose  Follow -up 
 ≤24 hrs from 
1st dose  Day 1  Day 1  Day 8 
 Day 8 Day 1 5  
Follow up 
Visit  
(±2 days)  Day 2 2 
Follow up 
Visit  
(± 2 days)  
Informed Consent  x       
Assess Inclusion/Exclusion  x x      
Medical History  x       
Physical Exam  x       
Vital Signs1 x x x x1 x1 x x 
Pregnancy  test2 x   x    x 
Record ABSSSI surgical procedures3 x       
Chemistry and Hematology L aboratory assessments4 x   x x x x 
Microbiology testing5 x       
Record prior or concomitant medications  x x x x x x x 
Administer IV oritavancin    x  x9   
Assess clinical cure6    x    
Immunoglobulin panel  x   x x x x 
Direct and Indirect Antiglobulin  Test7 x   x  x x 
Plasma Storage Samples for oritavancin antibody assay  x   x x x x 
Collect blood specimen for co mplement profile (C3, C4, 
CH50), serum tryptase, erythrocyte sedimentation rate 
(ESR), Haptoglobin level and C -reactive protein     x x   
Collect plasma for PK10     x x x x 
Assessment of adverse events8 x x x x x x x 
 
1 Vital signs include blood pressure, temperature, respiratory rate and heart rate. On Day 8 vitals will be collected at pre-dose, 1.5 hours after the start of infusion, at the end of the infusion, and 4 
hours after the start of infusion. 
Oritavancin diphosphate                                                                    Clinical Study Protocol MDCO-ORI-16-02 
The
 Medicines Company  
 
Confidential                      30 
 2 
Perform a local urine pregnancy test for female subjects of childbearing potential (may be omitted for females >2 years postmenopausal or surgically sterile). 
3 This includes but is not limited to aspiration, debridement, incision and drainage. 
4 Blood chemistry and hematology (Section 7.1.4 for listing of tests to be performed).  Unless otherwise indicated all laboratory tests will be performed by the site’s local laboratory.  
5 Microbiology testing should be performed per institution's Standard of Care (SOC). 
6 Clinical cure should be assessed by the investigator at Day 8. 
7 Direct and indirect antiglobulin testing will be done both at the local lab and also sent frozen to a central Lab.  Subjects with a positive direct or indirect antiglobulin test at the Day 22 visit must have 
the test repeated every 2 weeks until it returns to baseline or stabilizes. 
8 Adverse events and serious adverse events will be assessed from the time of informed consent through 22 days post first administration of oritavancin. 
9 Subjects should remain at the clinic for observation for at least 3 hours post the completion of this IV infusion or until all adverse events have resolved or stabilized.  A medically qualified team 
member must be onsite during this time to assess any adverse events.                                    
10 Time points for PK sample collection are Day 8 (pre-dose, end of infusion (3 hr.) , 6-hr. post infusion start), and on Day 15 and Day 22. 
Oritavancin diphosphate                                               Clinical Study Protocol MDCO-ORI-16 -02 
The Medicines Company  
 
Confidential                   31 
 6
.2. General Conduct of the Trial 
Written informed consent will be obtained from all subjects by the site staff member before any 
study specific procedure is performed.  
6.3. Screening Period (24 hours Prior to Day 1) 
The following procedures will be performed ≤24 hours prior to Day 1 to establish each 
c
andidate's general health and qualifications for enrollment into the study: 
 Obta in written informed consent 
 Ve rify inclusion/exclusion criteria 
 R ecord medical history and demographics 
 P erform a physical examination, including height and weight to determine body mass 
index (BMI) 
 Obta in vital sign measurements (blood pressure, heart rate, respiratory rate, and 
temperature) 
 C ollect blood specimens for hematology, serum chemistry, immunoglobulin panel, 
oritavancin antibody assay, direct and indirect antiglobulin test 
 A ur ine pregnancy test will be performed for female subjects of childbearing 
potential. This test may be omitted for females >2 years postmenopausal or surgically 
sterile.  
 Micr obiology samples, if obtained, per standard of care 
 R ecord medication history over the past 14 days, including over-the-counter (OTC), 
prescription drugs, vitamins and nutraceuticals (e.g., herbal supplements) 
 Asse ssment of AEs and SAEs starting from the time the informed consent form is 
signed  
 R ecord planned ABSSSI surgical procedures 
6.4. Day 1 Pre-dose 
The following pre-dose procedures will be performed at Day 1 prior to administration of 
orita
vancin: 
 C onfirm that the subject continues to meet inclusion and exclusion criteria including 
the verification of safety lab results 
 Vital si gns (blood pressure, heart rate, respiratory rate and temperature) 
 Collection of concomitant medication information 
 Asse ssment of AEs and SAEs 
 Randomize the subject 
Oritavancin diphosphate                                               Clinical Study Protocol MDCO-ORI-16 -02 
The Medicines Company  
 
Confidential                   32 
 6
.5. Treatment Period 
The enrollment process will be initiated only after confirmation of a subject’s eligibility.  Each 
suc
cessive subject will be assigned a unique subject identification number. 
If a subject is found to be ineligible after signing the informed consent, but prior to dosing, he or 
she will be considered a screen failure, the subject will not be enrolled, and oritavancin will not 
be administered. 
6.5.1. Day 1  
Ideally, treatment should be initiated within 4 to 6 hours after the subject is first seen on Day 1.  
 Admini ster oritavancin as a single IV infusion of 1200 mg over 3 hours 
 Vital si gns (blood pressure, heart rate, respiratory rate and temperature) 
 C ollection of concomitant medication information 
 Asse ssment of AEs and SAEs 
6.5.2. Day 8  Pre-dose 
 Obta in vital sign measurements (blood pressure, heart rate, respiratory rate and 
temperature) 
 C ollect blood specimens for hematology, serum chemistry, immunoglobulin panel, 
oritavancin antibody assay, direct and indirect antiglobulin test 
 C ollect blood specimen for complement profile (C3, C4, CH50) and serum tryptase, 
erythrocyte sedimentation rate (ESR), Haptoglobin level and C-reactive protein. 
 C ollect PK blood sample 
 A ur ine pregnancy test will be performed for female subjects of childbearing 
potential. This test may be omitted for females >2 years postmenopausal or surgically 
sterile.  
 Asse ssment of clinical cure 
 C ollection of concomitant medication information 
 Assessment of AEs and SAEs 
6.5.3.  Day 8  Post-dose 
 Admini ster oritavancin or placebo as a single IV infusion of 1200 mg over 3 hours 
 Obta in vital sign measurements (blood pressure, heart rate, respiratory rate, and 
temperature) at 1.5 hours after the start of the infusion, at the end of infusion and 4 
hours after the start of the infusion. 
 Collect blood specimens for hematology, serum chemistry, immunoglobulin panel, 
oritavancin antibody assay, direct and indirect antiglobulin test at the end of the 
infusion 
Oritavancin diphosphate                                               Clinical Study Protocol MDCO-ORI-16 -02 
The Medicines Company  
 
Confidential                   33 
  C ollect blood specimen for complement profile (C3, C4, CH50) and serum tryptase, 
ESR, Haptoglobin level and C-reactive protein. 
 C ollect PK blood samples at 3 hours (end of infusion) and 6 hours after the start of 
the infusion. 
 C ollection of concomitant medication information 
 Asse ssment of AEs and SAEs  
 S ubjects should remain in the administration setting for a minimum of 3 hours 
following the completion of the second IV infusion or until any AEs that occur are 
resolved or stable.  A medically qualified team member must be onsite during this 
ti
me to assess any adverse events. 
6.6. Follow-up Period 
6.6.1. Day 1 5 (±2 days) 
 Obta in vital sign measurements (blood pressure, heart rate, respiratory rate, and 
temperature) 
 C ollect blood specimens for hematology, serum chemistry, immunoglobulin panel, 
oritavancin antibody assay, direct and indirect antiglobulin test 
 C ollect PK blood sample 
 C ollection of concomitant medication information 
 Assessment of AEs and SAEs 
6.6.2. Day 2 2 (±2 days) 
 Vital si gns (blood pressure, heart rate, respiratory rate, and temperature) 
 C ollect blood specimens for hematology, serum chemistry, immunoglobulin panel, 
oritavancin antibody assay, direct and indirect antiglobulin test 
 C ollect PK blood sample 
 A urine pregnancy test will be performed for female subjects of childbearing 
potential.  This test may be omitted for females >2 years postmenopausal or surgically 
sterile.  
 Collection of concomitant medication information 
 Assessment of AEs and SAEs 
Oritavancin diphosphate                                               Clinical Study Protocol MDCO-ORI-16 -02 
The Medicines Company  
 
Confidential                   34 
 7. P
ROTOCOL ASSESSMENTS 
7.1. Assessment of Safety  
When blood draws and vital signs are done at the same time point, the following sequence 
should be followed: 1) vital sign assessment 2) blood draw for lab tests. 
7.1.1. Adver se events 
Subjects will be carefully monitored for AEs by the investigator during the designated study 
pe
riod (see Section 8 for details).   
7.1.2. P hysical examinations 
A physical exam will include head, eyes, ears, nose, throat (HEENT), heart, lungs, abdomen, 
skin, and extremities. BMI will be calculated based on height and weight collected at the 
Screening Visit. 
7.1.3. Vital sign s 
Vital signs (blood pressure, heart rate, respiratory rate, and temperature) will be assessed at the 
designated time periods as indicated in the Assessment Schedule. Blood pressure and heart rate 
must
 always be taken after the subject has been resting supine for 5 minutes. 
7.1.4. L aboratory assessments 
Specimens will be obtained at the designated time periods as indicated in the Assessment 
Schedule.  All clinical laboratory assessments will be performed by the site’s local laboratory 
a
nd shipped to the central laboratory for testing.  Additional local laboratory testing may be 
performed at the discretion of the investigator.  Any clinically significant (CS) laboratory 
finding
s that occur during the study should be followed to resolution per the 
I
nvestigator/Sponsor’s decision.  If a subject has a positive indirect antiglobulin test at baseline, 
that subj
ect will be replaced in the study. 
 Che mistry:  Blood urea nitrogen, serum creatinine, total bilirubin, direct bilirubin, 
alkaline phosphatase, aspartate aminotransferase, alanine aminotransferase, albumin, 
total protein, glucose, calcium, chloride, sodium, magnesium, potassium, uric acid, 
lactate dehydrogenase, bicarbonate, phosphorus 
 Hem atology:  Hemoglobin, hematocrit, white blood cell count (with automated 
diff
erential), red blood cell count, platelet count,  reticulocyte count, complete blood 
count and manual blood smears 
 Add itional Labs:   Complement profile (C3, C4, CH50) and serum tryptase, ESR, 
Ha
ptoglobin level and C-reactive protein. 
 Ur ine pregnancy test 
 Direct and Indirect antiglobulin test 
 Immunoglobulin panel assays :  Immunoglobulin M (IgM), immunoglobulin G 
(IgG); immunoglobulin E (IgE), immunoglobulin A (IgA) 
Oritavancin diphosphate                                               Clinical Study Protocol MDCO-ORI-16 -02 
The Medicines Company  
 
Confidential                   35 
  Assay for oritavancin antibodies 
 P lasma storage samples for drug dependent antibody ex vivo study  
7.2. Assessment of Efficacy 
Definition of clinical response 
 A subje ct is classified as “success” if all of the following are met: 
 C essation of spread or reduction of the lesion defined as: Cessation of spread of the 
re
dness, edema, and/or induration, or reduction in size (length, width, and area) of the 
redness, edema, and/or induration such that the size of the lesion is less than or equal 
to the size at baseline 
 R esolution (absence) of fever (temperature <37.7°C)  
 No r escue antibiotic medication 
Investigator assessment of clinical cure: 
At Day 8:  Complete or nearly complete resolution of baseline signs and symptoms of the 
prima
ry infection such that no further treatment with antibiotics is needed. 
A subje
ct cannot be classified as clinical cure if: 
 S ubject did not fulfill the criteria for clinical cure above 
 I nvestigator assignment of failure any time prior to Day 8 
 Subject dies (all-cause mortality) from the start of administration of oritavancin  
 I ncision and drainage after 48 hours of treatment that was unplanned prior to 
enrollment, with the exception of cellulitis where there is a conversion into an abscess 
or when an extension of the original incision is indicated 
 Initiation of non-study antibacterial drugs for treatment of other infections unless 
antibiotic lacks efficacy in the treatment of ABSSSI 
 S ubjects who otherwise do not meet the definition of clinical cure (e.g., lost to 
follow-up; oritavancin discontinued secondary to adverse reaction) 
A subject who is not classified as clinical cure will be classified as failure. 
7.3. Assessment of Pharmacokinetics 
Blood samples for pharmacokinetic analysis of oritavancin will be collected on Days 8 pre-dose, 
a
t 3 (end of infusion) and 6 hours after the start of study drug infusion. Subjects will have blood 
collected for PK on Day 15 and Day 22 as well.   
 
 
 
 
Oritavancin diphosphate                                               Clinical Study Protocol MDCO-ORI-16 -02 
The Medicines Company  
 
Confidential                   36 
 T
able 4: PK Blood Draw Schedule 
 Sample 
Number  Optimal Sample 
Time From Start of 
Infusion (h)  Sample Time Window  
Lower Limit 
(h) Upper Limit 
(h) 
 
 
DAY 8  
 1  
(before 
start of 
study 
drug)  Pre-dose -0.5 - 0.08 
2  
(at end of 
infusion)  3 hours  3 3.5 
3 6 hours  5 7 
DAY 15  4 PK sample at visit    
DAY 22  5 PK sample at visit    
 
Oritavancin diphosphate                                               Clinical Study Protocol MDCO-ORI-16 -02 
The Medicines Company  
 
Confidential                   37 
 8. A
DVERSE EVENTS 
8.1. Definitions  
8.1.1. Adver se Event  
An AE is defined as any untoward medical occurrence in a subject or clinical investigation 
subj
ect administered a medicinal product and which does not necessarily have a causal 
relationship with this treatment.  An AE can therefore be any unfavorable and unintended sign 
(including an abnormal laboratory finding), symptom, or disease temporally associated with the 
use
 of a medicinal product, whether or not considered related to the medicinal product.  
Planned hospital admissions and/or surgical operations for an illness or disease that existed 
before the study drug was given or the subject was randomized in a clinical study are not to be 
considered AEs. 
Subjects experiencing AEs should be followed clinically until their health has returned to 
baseline status or until all parameters have returned to normal or have otherwise been explained.  
I
t is expected that the investigator will provide or arrange appropriate supportive care for the 
subject if necessary.  
8.1.1.1. AE Severity  
The severity of an AE will be assessed by the investigator.  The investigator should ensure that 
any subject experiencing an AE receives appropriate medical support until the event resolves. 
AEs will be graded on a 3-point scale and reported as indicated on the CRF .  The  intensity of an 
AE is defined as follows: 
1 = Mild: Discomfort noticed, but no disruption to daily activity. 
2 = Moderate: Discomfort sufficient to reduce or affect normal daily activity. 
3 = Severe: Inability to work or perform normal daily activity. 
8.1.1.2. Study Drug Causality  
The relationship of an AE to study treatment will be assessed with consideration to the following 
criteria: 
 Te mporal relationship to the initiation of study medication 
 Response of the event to withdrawal of study medication 
 AE profile of concomitant therapies 
 Clinical circumstances during which the AE occurred 
 Subject’s clinical condition and medical history 
Categorization of causality will be designated by the investigator as stated below: 
1. Unlikely related  - Lack of reasonable possibility of a causal relationship - causal 
re
lationship between the event and the Investigational Medicinal Product (IMP).  This 
Oritavancin diphosphate                                               Clinical Study Protocol MDCO-ORI-16 -02 
The Medicines Company  
 
Confidential                   38 
 mea
ns that there are little to no facts (evidence) or arguments to suggest a causal 
relationship. 
2. Re asonable possibility  - Reasonable possibility of a causal relationship - causal 
re
lationship between the event and the IMP.  This means that there are facts (evidence) or 
a
rguments to suggest a causal relationship. 
8.1.2. S erious Adverse Event 
An SAE is any untoward medical occurrence that at any dose: 
 R esults in death, 
 Is life-threatening, i.e., the subject was, in the opinion of the investigator, at 
immediate risk of death from the event as it occurred (it does not include an event 
that, had it occurred in a more severe form, might have caused death), 
 Results in a significant, persistent or permanent change, impairment, damage or 
disruption in the subject's body function/structure, physical activities and/or quality of 
life, 
 Requires in-subject hospitalization or prolongs hospitalization, 
 I s a congenital anomaly/birth defect, or 
 I s another medically significant event that, based upon appropriate medical judgment, 
may jeopardize the subject and may require medical or surgical intervention to 
prevent one of the outcomes listed above (e.g., allergic bronchospasm requiring 
intensive treatment in an emergency department or home, blood dyscrasias or 
convulsions that do not result in hospitalization, or the development of drug 
dependency or drug abuse). 
A distinction should be drawn between serious and severe AEs.  Severity is an estimate or 
mea
sure of the intensity of an AE, while the criteria for serious AEs are indications of 
adverse subject outcomes for regulatory reporting purposes.  A severe AE need not 
ne
cessarily be considered serious and a serious AE need not be considered severe.  For 
e
xample, nausea that persists for several hours may be considered severe nausea, but not an 
SAE.  On the other hand, a myocardial infarction (MI) that may be considered minor could 
a
lso be an SAE if it prolonged hospitalization. 
When death occurs with an SAE, the cause of death must be reported as an SAE. “Fatal” will 
be reported as the outcome for these events. 
8.1.3. M edication Errors  
Medication error refers to any unintended error in the dosing and administration of the study 
drug as per instructions in the protocol.  Medication errors generally fall into 4 categories as 
follows: 
 wrong study medication 
 wrong dose (including dosing regimen, strength, form, concentration, amount); 
Oritavancin diphosphate                                               Clinical Study Protocol MDCO-ORI-16 -02 
The Medicines Company  
 
Confidential                   39 
  wr ong route of administration; 
 wr ong subject (i.e., not administered to the intended subject) 
Me
dication errors include occurrences of overdose and underdose of the study product(s), and 
misuse. 
Overdose :  Administration of a quantity of the study product given per administration or per day 
which is above the maximum recommended dose according to the reference safety information 
or protocol for the investigational product or comparator as applicable.  This also takes into 
acc
ount cumulative effects due to overdose.  
Underdose : Administration of a quantity of the study product given per administration or per 
day which is under the minimum recommended dose according to the reference safety 
information or protocol for the investigational product.  
Misuse : 
Intentional and inappropriate use of a medicinal product not in accordance with the 
pre
scribed or authorized dose, route of administration, and/or the indication(s) or not within the 
legal status of its supply (e.g., without prescription for medicinal products subject to medical 
pre
scription). 
8.1.4. Adver se Event of Special Interest (AESIs) 
An adverse event of special interest (serious or non-serious) is one of scientific and medical 
concern specific to the Sponsor’s product or program, which warrants ongoing monitoring and 
ra
pid communication by the investigator to the Sponsor. Such an event might warrant further 
investigation in order to characterize and understand it.  
The following AESIs have been identified for the study drug in this protocol: 
 H ypersensitivity/Infusion Related Reaction 
 P seudomembranous colitis/ Clostridium difficile -associated diarrhea 
 Oste omyelitis 
8.2. Procedure for Non-Serious Adverse Event Recording 
All non-serious AEs that occur during the designated study period (from signing the informed 
consent to 21 days following initial oritavancin administration) must be assessed and recorded on 
the sour
ce documents and eCRF, regardless of causal relationship to the study drug. 
8
.3. Procedure for Serious Adverse Event Reporting 
All SAEs that occur during the designated study period (from signing the informed consent to 21 
da
ys following initial oritavancin administration) must be reported to MDCO within 24 hours of 
a
wareness of the event using the provided study specific SAE/AESI Report Form.  The 
c
ompletion and processing of the SAE/AESI Report Form (paper) should follow the instructions 
provided in the SAE/AESI Report Form completion guidelines.  In addition to completing the 
S
AE/AESI Report Form, each SAE/AESI must be entered on the appropriate page of the eCRF.   
When death occurs with an SAE, the cause of death must be reported as an SAE.  “Fatal” will be 
re
ported as the outcome for these events 
Oritavancin diphosphate                                               Clinical Study Protocol MDCO-ORI-16 -02 
The Medicines Company  
 
Confidential                   40 
 T
he investigator must assess the causality for each SAE/AESI. 
MDCO will contact the investigator, if necessary, to clarify any of the event information. The 
investigator should provide any
 follow-up information for the event to MDCO as soon as it 
be
comes available. 
If the investigator is notified of a SAE/AESI that occurs during the post-study period, that he or 
she wishes to report to the Sponsor (e.g., an event suspected to be causally related to study drug), 
the e
vent should be reported through the process described above.  
Where appropriate, if required by local regulations or procedures, the investigator should report 
these events to the Institutional Review Board (IRB)/Ethics Committee (EC) and/or national 
regulatory authority in addition to the Sponsor. 
8.4. Procedure for Medication Error Reporting For Study Products 
Medication errors, with or without an associated AE, need to be recorded as medication errors in 
the e
CRF as described in Section 8.2. 
Me
dication errors with an associated SAE need to be recorded as medication errors in the eCRF 
and reported to the MDCO Global Pharmacovigilance as described in S ection 8.3. 
A mis-dosing protocol deviation (refer to Section 12.3 ) would need to be reported as a 
medication error if it was an “unintended error” as defined in Section 8.1.3. 
8
.5. Procedure For Reporting Adverse Events Of Special Interest 
(AESIs) 
All AESIs should be reported to MDCO within 24 hours.  The SAE/AESI Report Form should 
be
 utilized for reporting the AESI even if a serious outcome may not apply.  The SAE/AESI 
R
eport Form should indicate that the reported event is an AESI.  The site will also be asked to 
c
omplete a targeted questionnaire which obtains more information about the specific event. 
8
.6. Procedure For Rep
orting Pregnancies 
Occurrences of pregnancy/lactation exposure in a study subject or study subject’s partner, 
including pregnancies detected anytime from administration of oritavancin until 60 days after 
administration of oritavancin, must be reported within 24 hours using the Pregnancy Reporting 
f
orm.  In cases where a pregnancy occurs with an SAE, the SAE Reporting Form should be used 
to re
port the SAE/AESI and the Pregnancy Reporting Form should be used to report the 
pregnancy.  Any spontaneous abortion must be captured as an SAE.  When a pregnancy occurs 
without
 any intercurrent SAE, the Pregnancy Reporting Form may be submitted alone.  Follow-
up through pregnancy outcome is required if a pregnancy is detected during this study. 
The
 Medicines Company or its designee will contact the investigator, if necessary, to clarify any 
of the pregnancy information.  The investigator will provide follow-up information to MDCO or 
it
s designee as soon as it becomes available.  Additionally, if required by local regulations or 
proc
edures, the investigator will report pregnancies to the IRB/EC and/or national or local 
regulatory authorities. 
Oritavancin diphosphate                                               Clinical Study Protocol MDCO-ORI-16 -02 
The Medicines Company  
 
Confidential                   41 
 8
.7. Ongoing Safety Monitoring and Stopping Rules 
The Sponsor will be conducting ongoing review of the safety data (AEs, vitals and labs).  The 
study will be terminated if any of the following criteria are met: 1) any death which is considered 
possibly related to oritavancin or 2) any two or more subjects who experience any serious 
adverse event possibly related to oritavancin or 3) any three or more subjects who experience 
a
ny non-serious AE which is severe in intensity and considered possibly related to oritavancin. 
8.8. Procedure For Reporting Special Situations 
If there is an occurrence of a Special Situation event, defined in Section 8.1.4, report this 
oc
currence to the Sponsor as per Section 8.3, Procedure for Serious Adverse Event Reporting. 
Note
: The Special Situations event does not need to be serious to be reported on the SAE/AESI 
Report form. 
 
Oritavancin diphosphate                                               Clinical Study Protocol MDCO-ORI-16 -02 
The Medicines Company  
 
Confidential                   42 
 9. D
ATA COLLECTION 
An electronic data capture (EDC) system will be used for this trial.  All users will be trained on 
the technical features of the EDC as well as the content of the eCRF by qualified personnel prior 
to gaining access to the EDC.  A User ID/Password will be granted after training.  This ID is not 
to be sha
red amongst the study staff.  All users must have a unique account to enter or review 
data.  The eCRF should be filled out by the site 3 days after the Day 15 visit and 3 days after the 
Da
y 22 visit.  Any Clinically Significant lab data or AEs occurring after the second dose should 
be e
ntered within 24 hours in order to facilitate the Sponsor’s ongoing review of safety data.  It is 
not expected that the eCRF will serve as source for any data collected in this trial.  If there is a 
reason for a site to do so, it must be approved by DCO and documented in the site files. 
Prior to the database being locked, the investigator or designee will review, approve, and 
sign/date each completed eCRF.  This signature serves as attestation of the investigator’s 
re
sponsibility for ensuring that all data entered into the eCRF are complete, accurate, and 
authentic.  After the end of the trial, a copy of the data will be provided to the site.  This copy 
will contain the final data, an audit trail of activity on the data, and any queries and answers that 
were posted for data clarification.   
Oritavancin diphosphate                                               Clinical Study Protocol MDCO-ORI-16 -02 
The Medicines Company  
 
Confidential                   43 
 10. STA
TISTICAL PLAN 
This is a 20 subject, randomized, double-blind trial.  Subjects with ABSSSI will be included in 
this study.  Subjects will be recruited from approximately 5 centers in the US.  Subjects that 
qua
lify for entry into the study will be randomly assigned in a 3:1 ratio to receive either two IV 
doses of 1200 mg oritavancin one week apart or a single dose of 1200 mg oritavancin and a 
plac
ebo infusion one week apart.  The primary objective of this study is to evaluate the safety 
a
nd tolerability of two 1200-mg IV infusions of oritavancin when administered one week apart.  
Statistical methods and data presentation will be described in more detail in the Statistical 
Ana
lysis Plan (SAP) document. 
10.1. Sample Size  
Approximately 20 ABSSSI subjects will be evaluated to obtain safety information including the 
potential f
or antibody production related to oritavancin administration.  Study subjects will be 
randomized in a 3:1 ratio to all receive oritavancin with the first dose (20 subjects) and receive 
oritavancin with the second dose (15 subjects) or placebo (5 subjects).  
10.2. Randomization 
Subjects will be randomly assigned in a 3:1 ratio to receive either two doses of oritavancin one 
week apart or one dose of oritavancin and one dose of placebo one week apart.   
10.3. General Statistical Considerations and Definitions  
10.3.1. General Statistical Methods 
Continuous variables will be summarized using mean, standard deviation (SD), median, quartiles 
(first [ Q1] and third [ Q3] ), minimum, and maximum.  Categorical variables will be summarized 
using frequency and percentage.   
10.3.2. Analysis Population 
Two populations will be used for data analyses and/or presentation.   
10.3.2.1.
 Intent- to-Treat (ITT) Population  
The ITT population will include all subjects screened and randomized.  This will be the primary 
population for
 efficacy analysis. 
10.3.2.2. Safety Population 
The safety population will include all subjects who are dosed with IV oritavancin.  This will be 
the primary population for safety analysis.  
10.3.3.
 Analysis Windows and Baseline 
The observational period for the study includes Day 22 ±2 days.  Any event occurring beyond the 
defined observational period, even if collected on the CRF, will not be included in the planned 
Oritavancin diphosphate                                               Clinical Study Protocol MDCO-ORI-16 -02 
The Medicines Company  
 
Confidential                   44 
 statis
tical analysis.  However, all data, including that reported after the defined observational 
period, will be included in the subject data listings.   
Unless otherwise specified, the last evaluation prior to the initiation of dosing will be considered 
the “Baseline” evaluation for analysis of data.  
10.3.4. Missing Data Handling 
Unless otherwise specified, missing data will not be imputed and will be excluded from the 
associated analysis.  
10.4. Statistical Analyses 
All summaries will be presented by group.   
10.4.1. Demographic and Background Characteristics 
Subject demographics and baseline characteristics will be summarized using the Safety 
Population.   
10.4.2.
 Prior and Concomitant Medications 
S
eparate summaries of prior and concomitant medications will be provided for the Safety 
Population.  Prior medications are those received before the initiation of dosing on Day 1 while 
concomitant medications are those received after.  Medications will be coded with the World 
Health Organization (WHO) Drug Dictionary Enhanced.  
10.4.3. Safety Analysis 
10.4.3.1. Adverse Events  
The Medical Dictionary for Regulatory Activities (MedDRA) will be used for coding AEs.  An 
AE
 (classified by system organ class and preferred term) that occurs during the treatment period 
will be counted as a TEAE either if it is not present at baseline or if it is present at baseline but 
incr
eased in severity during the treatment period or follow-up period. 
The
 number (percentage) of subjects reporting TEAEs for each preferred term will be tabulated 
by system organ class, by system organ class and severity, and by s ystem organ class and 
re
lationship to oritavancin.  If more than one event occurred with the same preferred term for the 
same subject, the subject will be counted only once for that preferred term using the most severe 
or related occurrence for the summary by severity, or relationship to study drug, respectively.   
Listings of SAEs and AEs leading to treatment or study discontinuation will also be provided.   
10.4.3.2. Clinical Safety Laboratory Tests  
Clinical safety laboratory values and changes from baseline, including direct and indirect 
antiglobulin, immunoglobulin panel, and oritavancin antibody assay, will be summarized 
descriptively. Clinically significant values will also be flagged in a listing.   
Oritavancin diphosphate                                               Clinical Study Protocol MDCO-ORI-16 -02 
The Medicines Company  
 
Confidential                   45 
 10.4.3.3.
 Vital Signs  
Vital sign measurements and changes from baseline will be summarized descriptively at each 
sc
heduled time point. Potentially clinically significant changes will also be flagged in a listing.   
Oritavancin diphosphate                                               Clinical Study Protocol MDCO-ORI-16 -02 
The Medicines Company  
 
Confidential                   46 
 11. R
ECORDS RETENTION 
Current FDA regulations require all investigators participating in clinical study drug trials to 
maintain detailed clinical data for one of the following periods: 
 At lea st 2  years following the date on which a New Drug Application is approved by 
the FDA, or 
 Tw o years after the Sponsor notifies the investigator that no further application is to 
be filed with the FDA. 
Similarly, current EU Directives / Regulations and International Conference on Harmonization 
(ICH) guidelines collectively require that essential clinical trial documents (including case report 
forms) other than patient’s medical files must be retained for the following time period: 
 — for at least 15 years after completion or discontinuation of the trial,  
 — or for at least two years after the granting of the last marketing authorisation in the 
European Community and when there are no pending or contemplated marketing 
applications in the European Community,  
 — or for at least two years after formal discontinuation of clinical development of the 
study drug.  
Subject's medical files should be retained in accordance with applicable legislation and in 
accordance with the maximum period of time permitted by the hospital, institution or private 
practice.  The documents can be retained for a longer period, however, if required by the 
applicable regulatory requirements or by agreement with the sponsor.  
To c
omply with these requirements, the investigator will not dispose of any records relevant to 
this study without either (1) written permission from the Sponsor or (2) providing an opportunity 
for the Sponsor to collect such records.  The investigator shall take responsibility for maintaining 
adequate and accurate hard copy source documents of all observations and data generated during 
this study, including the hard copy or discs received from the Sponsor of the final data.  Such 
documentation is subject to inspection by the Sponsor or its agents, the FDA and/or other 
regulatory agencies. 
Oritavancin diphosphate                                               Clinical Study Protocol MDCO-ORI-16 -02 
The Medicines Company  
 
Confidential                   47 
 12. QUALI
TY CONTROL AND QUALITY ASSURANCE  
12.1. Monitoring  
The Sponsor has ethical, legal and scientific obligations to carefully follow this study in 
accordance with established research principles and applicable regulations.  The investigator, as 
part of his responsibilities, is expected to cooperate with the Sponsor in ensuring that the study 
adheres to the protocol and GCP requirements.   
As part of a concerted effort to fulfill these obligations, the Sponsor's monitor will visit the 
center(s) during the study in accordance with the Monitoring Plan set forth for this trial.  The 
investigator will permit the Sponsor to monitor the study as frequently as is deemed necessary 
and provide access to medical records/source documents to ensure that data are being recorded 
adequately, that data are verifiable, and that protocol adherence is satisfactory.   
1
2.2. Auditing  
The Sponsor may conduct audits at the study centers.  Audits will include, but not be limited to, 
study drug supply, presence of required documents, the informed consent process, and 
c
omparison of eCRFs with source documents.  The investigator agrees to permit audits 
conducted at a reasonable time in a reasonable manner. 
Regulatory authorities worldwide may also inspect the investigator during or after the study.  
The investigator should contact the Sponsor immediately if this occurs, and must permit 
regulatory authority inspections. 
12.3. Protocol Deviations  
This study will be conducted as described in this protocol, except for an emergency situation in 
which the protection, safety, and well-being of the subject requires immediate intervention, 
based on the judgment of the investigator (or a responsible, appropriately trained professional 
designated by the investigator).  In the event of a significant deviation from the protocol due to 
an emergency, accident, or mistake, the investigator or designee must contact the Sponsor 
(Clinical Project Director, Medical Director or Clinical Research Associate) at the earliest 
possible time.  This will allow an early joint decision regarding the subject’s continuation in the 
stud
y.  The investigator and the Sponsor will document this decision.  The IRB/EC will be 
informed of a
ll protocol changes by the investigator in accordance with the IRB/EC established 
procedure.  No deviations from the protocol of any type will be made without complying with all 
the 
IRB/EC established procedures. 
Any protocol deviations that will affect the subject’s safety or the study objectives may be 
considered a major protocol deviation upon review by the Sponsor.  In addition, any of the 
following deviations will be considered major protocol deviations: 
The following Protocol Deviations will require additional information in the eCRF explaining 
why the deviation occurred and what will be done to prevent it from re-occurring:  
 All Inclusion criteria violation 
 All Exclusion criteria violation 
Oritavancin diphosphate                                               Clinical Study Protocol MDCO-ORI-16 -02 
The Medicines Company  
 
Confidential                   48 
  P K sample not collected due to site error 
 Mis -Dosing: Subject was not dosed per the protocol instructions and therefore, greater 
than 120% or less than 80% of the correct dose was administered 
 
*If the mis-dosing was unintended, i.e. a medication error, the error should be reported as 
per instructions in Section 8.4, Procedure for Medication Error Reporting. 
Oritavancin diphosphate                                               Clinical Study Protocol MDCO-ORI-16 -02 
The Medicines Company  
 
Confidential                   49 
 13. ETHI
CS AND RESPONSIBILITY 
This study will be conducted in compliance with the protocol, the Sponsor’s standard operating 
procedures and/or guidelines, the US Food and Drug Administration (FDA) regulations, the ICH 
GCP
 guidelines, the Declaration of Helsinki and other local regulations, as applicable. 
13.1. Informed Consent 
Written informed consent will be obtained from all subjects (or their guardian or legally 
authorized representative) or, as per IRB guidelines, before any study-related procedures 
(inc
luding any pre-treatment procedures) are performed.  The investigator(s) has both ethical and 
legal responsibility to ensure that each subject (and their guardian or legally authorized 
re
presentative) being considered for inclusion in this study is given a full explanation of the 
protocol.  This shall be documented on a written informed consent form, which shall be 
approved by the same IRB or EC responsible for approval of this protocol.  Each informed 
consent form shall include the elements required by ICH, Part E6, Section 4.8 and any applicable 
local regulations.  The investigator agrees to obtain approval from the Sponsor of any written 
informed consent form used in the study, preferably prior to submission to the IRB or EC.  
Once the appropriate essential information has been provided to the subject and fully explained 
by the investigators (or a qualified designee) and it is felt that the subject understands the 
implications of participating, the subject and the investigator (or designee) shall sign the IRB- or 
EC-
approved written informed consent form.  The subject shall be given a copy of the signed 
informed consent form, and the original shall be filed appropriately, according to the institution.  
A second copy may be filed in the subject's medical record, if allowed by the institution. 
13.2. Institutional Review Board/Ethics Committee  
This protocol, the written informed consent form and any materials presented to subjects shall be 
submitted to the IRB or EC identified with this responsibility.  Notification in writing of 
approval must come from the IRB or EC chairman or secretary, to the investigator, either as a 
letter or as a copy of the appropriate section of the IRB or EC meeting minutes where this 
protocol and associated informed consent form were discussed.  The investigator will not 
participate in the decision.  If the investigator is an IRB or EC member, the written approval 
must indicate such non-participation in the voting session.  The investigator will submit status 
reports to the IRB or EC as required by the governing body.  The IRB or EC must be notified by 
the investigator in writing of the interruption and/or completion of the study; the investigator 
must promptly report to the IRB or EC all changes in research (protocol amendments) and will 
not make such changes without IRB or EC approval, except where necessary to eliminate 
apparent immediate hazards to human subjects.  In cases where it is necessary to eliminate 
immediate hazards to subjects, the IRB or EC must then be notified of the change as per local 
requirements.  The investigator is required to maintain an accurate and complete record of all 
written correspondence to and received from the IRB or EC and must agree to share all such 
documents and reports with the Sponsor.  
Oritavancin diphosphate                                               Clinical Study Protocol MDCO-ORI-16 -02 
The Medicines Company  
 
Confidential                   50 
 14. C
ONFIDENTIALITY 
All information generated in this study must be considered highly confidential and must not be 
disclosed to any persons not directly concerned with the study without written prior permission 
from the Sponsor.  However, authorized regulatory officials and Sponsor personnel will be 
allowed full access to the records.  All medications provided and subject bodily fluids and/or 
other materials collected shall be used solely in accordance with this protocol, unless otherwise 
agreed to in writing by the Sponsor. 
Only unique subject numbers in eCRFs will identify subjects.  Their full names may, however, 
be made known to a product regulatory agency or other authorized official if necessary. 
Oritavancin diphosphate                                               Clinical Study Protocol MDCO-ORI-16 -02 
The Medicines Company  
 
Confidential                   51 
 15. I
NVESTIGATOR AGREEME NT 
I have read and understand the protocol (including the Investigator’s Brochure) and agree that it 
contains all the ethical, legal and scientific information necessary to conduct this study.  I will 
personally conduct the study as described. 
I will provide copies of the protocol to all physicians, nurses and other professional personnel 
responsible to me who will participate in the study. I will discuss the protocol with them to 
assure myself that they are sufficiently informed regarding the new study drug oritavancin, the 
concurrent medications, the safety parameters, and the conduct of the study in general.  I am 
a
ware that this protocol must be approved by the IRB or EC responsible for such matters in the 
C
linical Study Facility where oritavancin will be tested prior to commencement of this study.  I 
agree to adhere strictly to the attached protocol.  I understand that this IRB or EC approved 
protocol will be submitted to relevant regulatory authorities by the Sponsor, as appropriate. I 
agree that clinical data entered on CRFs by me and my staff will be utilized by the Sponsor in 
va
rious ways such as for submission to governmental regulatory authorities and/or in 
combination with clinical data gathered from other research sites, whenever applicable.  I agree 
to allow Sponsor monitors and auditors full access to all medical records/source documents at the 
research facility for subjects screened or randomized in the study. 
I agree to provide all subjects with informed consent forms, as required by government and ICH 
regulations. I further agree to report to the Sponsor any adverse experiences in accordance with 
the terms of this protocol, ICH guideline, Part E6, Section 4.11, and applicable local regulations.  
 
Principal Investigator (Signature)  
  Date  
Principal Investigator (Printed Name)   Original Protocol Version  1 
 
Institution Name    
 
 
Oritavancin diphosphate                                               Clinical Study Protocol MDCO-ORI-16 -02 
The Medicines Company  
 
Confidential                   52 
 16. R
EFERENCES 
16.1. Publications 
Dryden MS. Skin and soft tissue infection: microbiology and epidemiology. Int J Antimicrob 
Agents. 2009; 34 (Suppl 1):S2-7. 
ORB
ACTIV (oritavancin) [package insert] Parsippany, NJ: The Medicines Company; 2016. 
Or
itavancin Investigator’s Brochure, Edition 10, March 2015. 
Aggr
egate Report of the Infusion-related Reaction Following the Second Infusion in the 
MDCO-ORI-15-02 Study; August 26, 2015. 
Follow up to the Agg
regate Report “Follow-Up Regarding Infusion-Related Reactions 
Following a Repeated Dose in a Phase I Multiple Dose Study (Study MDCO-ORI-15-02)”; 
J
uly 22, 2016. 
 